Clinical Trials

Acoustic neuromas (also known as vestibular schwannomas) are benign slow growing tumors that arise from the vestibular portion of the eighth cranial nerve. Current treatment options include microsurgery, stereotactic radiosurgery and observation, using a “wait-and-scan” approach. The primary objective of this study is to compare long-term quality of life outcomes between treatments for sporadic acoustic neuromas.

The purpose of this study is to evaluate whether the administration of aspirin can delay or slow tumor growth and maintain or improve hearing in  patients with vestibular schwannoma (VS).

The purpose of this study is to evaluate the benefit of using intravenous fluorescein sodium (FS) and YELLOW 560 nm microscope filter (YE560) during surgery for vestibular schwannomas (VS), Meningioma, Head and Neck Paraganglioma, or Head and Neck Schwannoma and to determine the optimum FS dose and timing to be used with the YE560 device.

The purpose of this study is to assess the use of AR-42 in adult patients undergoing NF2-tumor removal. AR-42 is a small molecule which crosses the blood brain barrier (BBB) in rodents, but the investigators are not certain yet if it will penetrate human Vestibular Schwannoma. Meningiomas are outside the BBB, but also seem to be unusually resistant to all current medical treatments.

The objectives of this study are to determine the impact of omega-3 supplementation on promoting facial nerve function recovery, and to determine the impact of omega-3 supplementation on Vestibular schwannoma (VS) tumor control.

The goal of this study is to correlate protein content in vestibular schwannomas and cerebrospinal fluid to patient outcomes, imaging findings, and other relevant clinical endpoints in patients who presented with both this tumor type and hydrocephalus.

The purpose of the study is to conduct cognitive testing of the recently published Mayo Clinic Vestibular Schwannoma Quality of Life (VSQOL) Index.